RxDoctor Payments Data

Simon Powell, MD

Radiation Oncology · New York, NYNPI 1487670782

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Astrazeneca UK Limited at 49.4% of the total. Reporting peaked in 2019 at $10,226 and has fallen 88.0% since, to $1,224 in 2023. Among radiation oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,572in general payments, 2019–2025

Across 18 payments — averaging $1087.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$10K
  • F. Hoffmann-la Roche AG$5K
  • AstraZeneca$4K
  • Varian Medical Systems, Inc.$550
$208,108in research payments, 2019–2025

Across 1 payment — averaging $208,108 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$208K

What the payments were for

  • Consulting fees$11,00356%
  • Travel & lodging$7,80140%
  • Food & beverage$7694%

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$19,572 in reported general payments places this provider in the 90th percentile of 397 radiation oncology providers in New York.

See all radiation oncology providers in New York

Medicare billing

Part B allowed, 2024
$51,217
Medicare patients
99
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →